British Life Sciences Startup Fighting bio A community version for researchers late this year has secured the round of € 1.9 million pre-marks in an oversscreen scientist to launch their virtual scientist platform to discover the drug.
The fund was led by the B2 Venture with the participation of Heartfelt, Rule 30 and several strategic angel investors. With fresh capital, Kin Bio will increase its client base, increase its AI capacity and scale its team.
“The future of drug discovery is not just better equipment and data, it is smart integration. We see a future where an AI-powered platform combines this fragmented landscape, turning thousands of isolated solutions into an integrated engine for breakthroughs“Said PhilippoCEO and Cain Bio co-founder. “We are happy to win reputable investors who support our mission to create pioneer Virtual Scientist platforms for drug discoveryThe “
Established in 2024, Cain Bio is creating an AI-Native Virtual Scientist platform for drug discoveries. Its unified platform integrates in virtual scientists, an agent marketplace and skeletal infrastructure to streamline “All things by reviewing literature and editing wet-lab from bioinformatics“. To accelerate research with investors and active pilots through its border programs, to accelerate research at the target bio and combine the drug invention with the AI-powered platform designed to unlock smart, smart innovation.
The team includes skills in AI, Bioinformatics, Cloud infrastructure and drug discovery:
- Philippo Abondenza (CEO) did a PhD in Bioinformatics and was previously a product director in LifeBight, where he developed and scale multiple AI-driven platforms to help pharma identify and analyze the correct information.
- Mark Davis (CDSO – Chief Data and Scientific Officer), brings more than 20 years of experience in development of technology and data products for life science. He was SVP Informatics and Data on the Benivilant AI and earlier was a technical leader of the EMBL-EBI, where he created large open biomedical resources like ChemBL and Surechembele.
- Bogdan Ursa (CTO) is a cloud infrastructure expert that brings more than 10 years of experience that provides large -scale digital systems across multiple cloud suppliers and earlier worked on lifeboight.
Cain Bio is watching one of the biggest challenges of drug discoveries: expensive and fragmented research and development processes that are reported to have taken a single drug across hundreds of scientists to market 3.7 million hours.
According to data provided by Cain Bio, the drug discovery genre market is about to generate $ 96 million in the coming years. Although there are distinct technologies to support researchers throughout the daily work, Cain Bio believes that there is no unified structure to attach them, resulting in productivity as a result.
The startup creates an integrated platform and closes this gap that flows from the discovery to development.
Already running through the Frontier Program, Kin Bio has launched three pilots projects, has achieved three commercial partnerships and won a European grant from the ELSA Industrial Award for its AI innovation.
“Cain Bio Biootake is creating the missing level: an AI-Native Agentic infrastructure that defines a new global and fragmented market, defining how the drug is discovered. Bold, timely and converter of their groundbreaking methods to orchestrate all relevant equipment and solutions to a collective virtual scientist platform“, Said Andreas GoeldiB2 partner in Ventures. “We are delighted to support this strong party. From the beginning we have been fascinated by their scientific depth, technical performance and a unique mixture of business wise.“
[publish_date
